-
公开(公告)号：US10780118B2
公开(公告)日：2020-09-22
申请号：US14422640
申请日：2013-08-20
IPC分类号： A61K35/17 , C07K14/705 , C07K14/725 , C07K14/715 , C07K16/28 , C07K16/32 , C07K16/40
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20180200298A1
公开(公告)日：2018-07-19
申请号：US15817002
申请日：2017-11-17
申请人： Fred Hutchinson Cancer Research Center , Seattle Children's Hospital, dba Seattle Children's Research Institute
IPC分类号： A61K35/17 , C07K16/40 , C07K14/705 , C07K16/32 , C07K16/28 , C07K14/715 , C07K14/725
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20210052649A1
公开(公告)日：2021-02-25
申请号：US17015995
申请日：2020-09-09
申请人： Fred Hutchinson Cancer Research Center , Seattle Children's Hospital, dba Seattle Children's Research Institute
IPC分类号： A61K35/17 , C07K14/705 , C07K14/725 , C07K14/715 , C07K16/28 , C07K16/32 , C07K16/40
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US10736918B2
公开(公告)日：2020-08-11
申请号：US15817002
申请日：2017-11-17
IPC分类号： A61K35/17 , C07K14/705 , C07K14/725 , C07K14/715 , C07K16/28 , C07K16/32 , C07K16/40
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20200078405A1
公开(公告)日：2020-03-12
申请号：US16657666
申请日：2019-10-18
申请人： Fred Hutchinson Cancer Research Center , Seattle Children's Hospital, dba Seattle Children's Research Institute
IPC分类号： A61K35/17 , C07K16/40 , C07K16/32 , C07K16/28 , C07K14/715 , C07K14/705 , C07K14/725
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US11065278B2
公开(公告)日：2021-07-20
申请号：US15969438
申请日：2018-05-02
IPC分类号： C12N5/0783 , A61K35/17 , C07K14/725 , C07K16/28 , C07K16/30 , A61K39/00 , A61K35/12
摘要： The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific CD8+ T cells in the presence of tumor-specific, subset specific genetically modified CD4+ T cells, wherein the CD4+ T cells confer and/or augment a CD8+ T cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific CD8+ T cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20160095883A1
公开(公告)日：2016-04-07
申请号：US14868038
申请日：2015-09-28
申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services , Fred Hutchinson Cancer Research Center
IPC分类号： A61K35/17 , A61K39/395
CPC分类号： A61K35/17 , A61K39/3955 , A61K2039/505 , C07K14/71 , C07K14/72 , C07K16/28 , C07K16/2803 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2319/00 , C12N15/85 , C12N2740/15043
摘要： The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject using immunotherapy to target and eliminate adipocytes.
-
公开(公告)号：US20150306141A1
公开(公告)日：2015-10-29
申请号：US14422640
申请日：2013-08-20
申请人： Fred Hutchinson Cancer Resesarch Center , Seattle Children's Hospital, dba Seattle Children 's Research Institute
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
摘要翻译： 本发明提供核酸，载体，宿主细胞，赋予和/或增加由细胞免疫治疗介导的免疫应答的方法和组合物，例如通过过继转移CD8 +中央记忆T细胞或中央记忆T细胞与CD4 + T细胞的组合， 被遗传修饰以表达嵌合受体。 在实施方案中，遗传修饰的宿主细胞包含核酸，其包含编码配体结合结构域的多核苷酸，包含定制的间隔区的多核苷酸，包含跨膜结构域的多核苷酸和包含细胞内信号转导结构域的多核苷酸。 已经令人惊奇地发现，间隔区的长度可以影响嵌合受体修饰的T细胞在体外识别靶细胞的能力并影响嵌合受体修饰的T细胞的体内功效。 还描述了通过该方法制备的药物制剂及其使用方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.032 秒)
